Drug General Information
Drug ID
D07TMR
Former ID
DNC001687
Drug Name
ISIS 23722
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 3 [523959]
Company
Isis Pharmaceuticals
Target and Pathway
Target(s) Baculoviral IAP repeat-containing protein 5 Target Info Modulator
KEGG Pathway Hippo signaling pathway
Hepatitis B
Pathways in cancer
Colorectal cancer
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Angiogenesis
Pathway Interaction Database Aurora B signaling
Validated targets of C-MYC transcriptional activation
FOXM1 transcription factor network
Aurora A signaling
Reactome Separation of Sister Chromatids
Resolution of Sister Chromatid Cohesion
RHO GTPases Activate Formins
Mitotic Prometaphase
WikiPathways IL-4 Signaling Pathway
Apoptosis-related network due to altered Notch3 in ovarian cancer
Mitotic Metaphase and Anaphase
Mitotic Prometaphase
Apoptosis
Interleukin-11 Signaling Pathway
Apoptosis Modulation and Signaling
References
Ref 523959ClinicalTrials.gov (NCT01630733) A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer. U.S. National Institutes of Health.